Pharma BD Deal Intelligence
Celgene Corporation / Impact Biomedicines
2018 · Acquisition/Merger · $7.0B · Complete
Announcement Sentiment
88
Strongly positive
Outcome Score
54
Mixed — partial payoff, real shortfalls.
Celgene acquired Impact Biomedicines for up to $7B for fedratinib.
Key facts
- Announced Jan 07, 2018
- Closed Jan 31, 2018
- Deal value $7.0B
- Deal type Acquisition/Merger
- Therapeutic area Oncology
- Key assets fedratinib
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals